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ABSTRACT 
Cancer-targeting peptides as ligands for targeted delivery of anticancer drugs or drug carriers 
have the potential to significantly enhance the selectivity and the therapeutic benefit of current 
chemotherapeutic agents.  Identification of tumor-specific biomarkers like integrins, 
aminopeptidase N, and epidermal growth factor receptor as well as the popularity of phage 
display techniques along with synthetic combinatorial methods used for peptide design and 
structure optimization have fueled the advancement and application of peptide ligands for 
targeted drug delivery and tumor detection in cancer treatment, detection and guided therapy.  
Although considerable preclinical data have shown remarkable success in the use of tumor 
targeting peptides, peptides generally suffer from poor pharmacokinetics, enzymatic instability, 
and weak receptor affinity, and they need further structural modification before successful 
translation to clinics is possible. The current review gives an overview of the different 
engineering strategies that have been developed for peptide structure optimization to  confer 
selectivity and stability. We also provide an update on the methods used for peptide ligand 
identification, and peptide-receptor interactions. Additionally, some applications for the use of 
peptides in targeted delivery of chemotherapeutics and diagnostics over the past 5 years are 
summarized. 
 
 
Keywords: 
Cancer Targeting Peptides; Phage Display; Spot Synthesis; Integrins; Aminopeptidase N; 
Targeted drug delivery; Tumor imaging 
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INTRODUCTION 
A wide array of strategies have been developed over the past two decades to enhance the 
selective delivery of chemotherapeutic drugs to the tumor site, reduce their toxicity, and 
overcome the emergence of multidrug resistance in tumors [1, 2].  One avenue to accomplish this 
feat is the targeted delivery of therapeutic molecules to the tumor cells, or tumor 
microenvironments via ligands that are specific for tumor-expressed markers or receptors. By 
studying the distinct nature of the tumor tissue and its microenvironment researchers have 
discovered that tumor cells express various biomarkers that normal cells do not express or 
express at a much lower level [3]. These markers are mostly proteinous in nature. Identification 
and characterization of ligands with high affinity for these markers can lead to selective 
accumulation of cytotoxic molecules at the tumor site [4].  In this regard, different ligands have 
been identified and studied for tumor selective drug targeting, such as antibodies, peptides, 
aptamers, affibodies, hormones and low molecular weight compounds, such as folate and some 
vitamins.  These ligands allow specific delivery of drugs to cancer cells either via direct chemical 
conjugation, or indirectly by their conjugation to the surface of different drug delivery systems, 
such as liposomes and micelles. 
 
In recent years, peptides and peptidomimetics have gained attention as an alternative to popular 
antibodies and affibodies as cancer targeting ligands.  Peptide-based therapeutics offer multiple 
advantages.  Their small size allows easy penetration into deep tissues, they can be less 
immunogenic, and they can be synthesized easily using automated solid phase methodology, 
allowing rapid synthesis with good yields and in a cost effective manner.  Peptide conjugation to 
different cargos is much easier and more reproducible than conjugation with large proteins.  
Moreover, peptides display higher stability during different storage conditions [5]. 
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Peptides suffer from some disadvantages, such as poor enzymatic stability, difficulty maintaining 
secondary structure, and fast renal clearance. In this review, we summarize recent strategies for 
developing peptide analogs with enhanced biological and pharmacokinetic properties through the 
design and optimization of various tumor targeting peptide ligands. These strategies can help in 
translating cancer-targeted peptide ligands to clinical settings. We focus on three potential 
molecular markers in tumor targeting research, namely, integrins, aminopeptidase N, and human 
epidermal growth factor.  Finally, some of the recent studies for applications of tumor targeting 
peptides in cancer-targeted therapeutics and in tumor diagnostics are presented. 
 
1. TARGETS IN SOLID TUMORS 
Several receptors that are overexpressed in the tumor environment and less expressed in normal 
(non-cancerous) tissues have been identified [6, 7].  In this section, we will discuss three distinct 
molecular markers for tumor targeting. 
 
INTEGRINS 
Integrins are heterodimeric membrane glycoproteins that are composed of non-covalently 
attached α- and - subunits.  The different combinations of α- and -subunits (24 distinct 
heterodimers) account for the ligand binding specificity and signaling pathway of each integrin. 
Integrins are cell adhesion receptors for extracellular matrix proteins, growth factors, cytokines, 
and immunoglobulins.  When integrins bind to their extracellular ligands a signaling cascade that 
regulates cell differentiation, proliferation, apoptosis and migration is induced [8, 9].  Some 
subtypes of integrins such as αvβ3, αvβ5, and α5β1 are over-expressed on cancer cells, and they 
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are found to have diverse roles in different stages of cancer, including tumor growth, invasion, 
angiogenesis, cancer cell transformation, and metastasis. Particularly, αvβ3 integrin subtype that 
is upregulated on angiogenic endothelial cells and on various tumor cell lines plays a major role 
in angiogenesis, tumor neovascularization, and tumor metastasis [7]. The angiogenic pathway is 
induced by fibroblast growth factor (b-FGF) or tumor necrosis factor alpha (TNF- α).  The 
integrin αvβ5 is involved in angiogenesis as well, but through a pathway stimulated by vascular 
endothelial growth factor (VEGF) or transforming growth factor alpha (TGF-α). Studies have 
reported that integrins recognize the extracelluar matrix proteins through the RGD (Arg-Gly-
Asp) peptide sequence found in the native ligands such as fibronectin, vitronectin, plasminogen, 
prothrombin, laminin, and osteopontin [10, 11].  Peptides or peptidomimetics containing the 
RGD motif efficiently block these integrin–ligand interactions, and are therefore being 
extensively applied for cancer-targeted therapeutics and in tumor diagnostics [12, 13]. 
 
AMINOPEPTIDASE N 
Aminopeptidase N (APN) or CD13 is a Zn2+ dependent integral membrane enzyme present in a 
number of human organs, tissues and cell types, such as endothelial cells, epithelial cells, 
fibroblasts, and leukocytes [14, 15].  APN is described as a multi-functional protein as it 
catalyzes the cleavage of neutral amino acids from the N-terminal end of the peptides, [16] as 
well as plays a role in some cell functionalities including antigen presentation, angiogenesis, 
tumor cell invasion, and metastasis. It also plays key role in physiologically important processes 
such as protein maturation, degradation of peptides, and cell cycle control [17].  Specific APN 
isoforms are highly expressed in various tumors, such as head and neck squamous-cell 
carcinoma, acute myloid leukemia, prostate cancer and colon cancer. Besides, APN is expressed 
on angiogenic blood vessels, and the isoforms in angiogenic vessels are different from the APN 
6 
 
forms expressed by the endothelium of normal blood vessels [18].  Reports have shown that 
tripeptide NGR (Asn-Gly-Arg) can specifically bind APN, and therefore NGR is gaining 
popularity as an efficient ligand for developing peptide-based delivery system targeting tumors. 
 
HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 
Epidermal growth factor receptor (EGFR) is a glycoprotein consisting of an extracellular N-
terminal binding domain, a hydrophobic transmembrane region and an intracellular C-terminal 
tyrosine kinase (TK) domain.  EGFR belongs to a family of receptors consisting of four different 
types of proteins (EGFR, ErbB-2, ErbB-3, and ErbB-4) that are activated following binding to 
their ligands which include epidermal growth factor (EGF), transforming growth factor-α 
(TGFα), amphiregulin, heparin-binding EGF-like growth factor, betacellulin, and epiregulin [19, 
20]. A signal that hits an individual receptor activates various signaling pathways that promote 
different cell processes such as, proliferation, angiogenesis, tumor survival, and metastasis. 
EGFR activation normally leads to cellular growth and its signaling can provide substantial 
advantages in tumor cells’ survival, therefore, specific EGFR inhibition is one of the key 
strategies in cancer therapy [21]. EGFR receptor overexpression has been implicated in different 
types of human cancers, and it has been involved in cancer progression and poor prognosis.  
Numerous EGFR blockers have been investigated which include anti-EGFR monoclonal 
antibodies, such as cetuximab (clinically approved), antibody-drug conjugates, and antisense 
oligonucleotides.  In addition to direct EGFR-inhibition therapies, significant research utilized 
EGFR-binding ligands for conjugation on different nanosystems surfaces to achieve specific 
tumor drug delivery and internalization.  Small peptides such as YHWYGYTPQNVI (GE11) and 
LARLLT have been identified as effective ligands for drug carriers for EGFR targeting [22, 23]. 
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2. METHODS FOR DISCOVERY OF HIGHLY SPECIFIC TUMOR TARGETING 
PEPTIDES 
Peptides that target cancer have been discovered by the rational design approach or random 
combinatorial methods. The rational design approach involves selection of an endogenous 
peptide sequence that interacts with a specific receptor, followed by structural optimization using 
standard synthetic methods such as alanine scan, D-amino acid scan, and truncation of N- and C- 
terminal residues to identify receptor binding regions.  The minimal sequence identified is then 
used in different peptide-receptor targeting strategies.  Peptides identified by the rational design 
approach are octreotide against somatostatin receptor, [24] bombesin against bombesin receptor, 
[25] and bradykinin analogues against bradykinin receptor [26].  In contrast, combinatorial 
peptide libraries enable the discovery of high-affinity peptide ligands to a vast number of 
receptors including ones that have unknown endogenous ligands by random peptide sequence 
search.  The most common combinatorial peptide library methods (phage display, one-bead one 
compound (OBOC) combinatorial bead library, [27, 28] and SPOT synthesis [29]) are discussed 
below.  The sequences identified by library methods are also subjected to structural optimization 
to make them fit for therapeutic use. 
 
PHAGE DISPLAY.  A phage display library is created by preparing a random mixture of phage 
clones with each displaying a single peptide on its surface.  The library is then exposed to intact 
cell or a protein target of interest present on a solid support (in vitro) or directly in mice (in vivo) 
[30].  Following this, the cells or the protein are collected, washed to elute all non-bound phages, 
and then amplified to produce the hit peptide for encoding the peptide sequence.  The screening 
of phage display peptide libraries has been reported in cancer patients as well [31, 32] . This 
technique allows peptide selection without any knowledge of the receptor, facilitating the 
8 
 
development of targeted therapies.  In general, the phage display method has shown great 
success in generating multiple lead peptides for the development of tumor-targeted therapeutics 
[33, 34]. 
 
ONE-BEAD-ONE-COMPOUND LIBRARY.  The one-bead-one-compound (OBOC) 
combinatorial bead library is a synthetic method for generating combinatorial libraries [28]. This 
method involves creation of an entirely random library on a polymer support, such as Tentagel, 
using split mix synthesis. The library is created by dividing the resin beads into a number of 
equal portions, with each portion having a single amino acid coupled to it.  After reaction 
completion, all the resin beads are combined, thoroughly mixed, and once again divided equally 
followed by coupling of the second amino acid.  The steps are repeated until the desired peptide 
length is reached.  This method allows inclusion of unnatural amino acids in the sequence, and it 
has been utilized in the discovery of many cancer targeting peptides [35, 36]. 
 
SPOT SYNTHESIS.  SPOT synthesis on functionalized cellulose membranes allows the 
creation of a random new library or a library based on the lead peptide sequence identified using 
the aforementioned methods.  The library is synthesized on the membrane in the form of peptide 
array, using SPOT synthesis, which is then screened against purified protein or intact cells to 
identify peptides with specific binding affinity for the protein or the cell line [37]. Ahmed et al. 
developed a peptide array library based on the lead peptide sequence p160 (12-mer peptide 
identified by phage display) to screen for peptides with specific and high affinity for breast 
cancer cell lines [38]. Similarly, screening of NGR peptides using a synthetic peptide array 
library on cellulose membrane led to the identification of peptides with high and specific binding 
for APN (CD13+) expressing cancer cells [39]. 
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3. TUMOR TARGETING PEPTIDES 
Currently, the peptide tumor-targeted therapies follow two main strategies: i) targeting of tumor 
cells, via tumor associated antigens, specifically expressed or overexpressed by tumor cells, and 
ii) targeting of tumor vasculature via vascular overexpressed antigens.  The goal of the first 
strategy is the selective targeted delivery of cytotoxic moieties to cancer cells, with the 
consequent death of tumor cells and low or no damage to healthy tissues.  In the second strategy, 
the goal is to target tumor vessels and impair them through inhibition of pro-angiogenic growth 
factors, which produces tumor starvation and reduced tumor cell access to the blood stream 
causing reduced metastasis.  A full database of tumor homing peptides was recently published 
[40]. The selective delivery of therapeutics such as radionuclides, cytotoxic entities, and other 
agents to tumors using peptide ligands is an extremely effective targeting approach, and holds 
great promise in cancer therapy and diagnosis [41]. While it is not feasible to discuss all potential 
cancer targeting peptides discovered so far, here we focus on some of the potential peptide 
sequences which had their in vivo targeting capacity evaluated (Table 1). 
 
TUMOR CELL SURFACE RECEPTOR TARGETING PEPTIDES 
Tumor targeting peptides that bind proteins involved in biological functions such as cell surface 
receptors, growth factor receptors and cell adhesion molecules are exploited for targeting a 
variety of cancers.  These peptides have been identified using phage display; therefore, in some 
cases the specific receptor is not yet known. 
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Table 1. Tumor targeting peptides isolated by in vivo biopanning 
 
 
BREAST CANCER.  Screening using an in vitro phage-display peptide library against WAC2 
neuroblastoma cells yielded a linear peptide p160 (Fig. 1) [42].  It was found that p160 
internalizes into MDA-MB-435 cells, and clusters at the cellular membrane.  131I-labeled p160 
intravenously injected in mice specifically accumulated in the breast tumor xenografts compared 
to heart, liver, spleen, and brain, and the tissue perfusion of the mice decreased the radioactivity 
in nonspecific tissue [43].  Ahmed et al. used a peptide array-cell binding assay to identify better 
Cancer Type Peptide Sequence (Name) Receptor 
Tumor Specific   
Breast VPWMEPAYQRFL  (p160) - 
 CRKRLDRN (AP1) IL-4R 
 SMDPFLFQLLQL (SP90) - 
Prostate FRPNRAQDYNTN  (DUP-1) - 
Hepatocarcinoma YHWYGYTPQNVI  (GE11) hEGFR 
TACHQHVRMVRP  (WP05) - 
 AGKGTPSLETTP (A54) - 
Pancreatic Penetratin sequence conjugated G7-18NATE Grb7 
SHGFSRHSMTLI  (PA1) - 
Gastric SWKLPPS - 
Tumor Vasculature 
Tumor angiogenic vessels 
 
CDCRGDCFC  (RGD-4C) Integrins 
CNGRCVSGCAGRC  (NGR) APN 
Tumor lymphatic vessels CGNKRTRGC  (LyP-1) p32/gC1qR 
The selection method for all the peptides was phage display mouse xenograft, except for 
LyP-1 where ex vivo/in vivo screen on mouse xenograft was used.   Grb7; growth factor 
receptor-bound protein 7, APN; Aminopeptidase N, -; not determined. 
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analogues of p160.  Using a synthetic peptide array of 70 linear peptide sequences based on p160 
peptide as a lead, a 10-mer p160 analogue (peptide 18, Fig. 1) that displayed 3-fold better 
binding compared to p160 for the MDA-MB-435 and MCF-7 cancer cells was identified [38].  
To understand the structural basis for the enhanced binding of peptide 18 compared to p160, the 
NMR solution structures of p160 and 18 in trifluoroethanol was elucidated, and showed that 
peptide 18 is more helical than p160 (Fig. 1C) [44].  The helical structure and the presence of 
distinct binding faces supported the better performance of peptide 18.  Peptide p160 analogue 
(peptide 18) was further optimized for improved binding and proteolytic stability to yield 10-mer 
peptide 18-4 (Fig. 1B) with two D-amino acid residues [44].  Peptide 18-4 maintained proteolytic 
stability in the presence of human serum and liver homogenate from mice and displayed up to 
3.5-fold enhanced binding to cancer cells compared to p160 peptide analogue 18 [44].  
 
Peptide AP1 (CRKRLDRN) is another breast homing peptide identified using phage display that 
selectively binds to the interleukin 4 receptor (IL-4R).   Interleukin binding to the IL-4R receptor 
increases the expression of anti-apoptotic proteins such as cFLIP/CFLAR, PED/PEA15 and Bcl 
(BCL family proteins) which counteracts the ability of cancer drugs to cause cell death. 
Therefore, targeting the IL-4R receptor enhances the therapeutic efficacy of anticancer drugs 
[45]. The targeting ability of AP1 peptide was assessed in vitro using a genetically expressed 
library of elastin like polypeptide (ELP) polymers containing different number of tumor targeting 
AP1 peptide in cancer cells.  The results showed that the fluorescently labeled ELP polymer 
containing six AP1 peptides enhanced tumor-specific targeting and the uptake efficiency in 
MDA-MB-231 breast cancer cell lines.  Fluorescence images using near-infrared fluorescence 
(NIRF) live  
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Fig. (1).  (A) Sequence of first generation p160 peptide and the second generation engineered 
p160 analogues, namely 18 and 18-4.  (B) Chemical structure of peptide 18-4. Peptide 18-4 
contains two D-amino acids (blue) and x is norleucine (Nle).  (C) The three dimensional NMR 
solution structures of p160 (left) and 18 (right) in 2,2,2,-trifluoroethanol (TFE). 
(B)
18-4
(A) 
(C) 
13 
 
optical imaging in MDA-MB-231 breast cancer-bearing mice showed that the [AP1-V12]6 
polymer accumulated in tumors after 10 min from intravenous injection, peaked after 6 h, and 
was maintained up to 24 h.  Biodistribution studies showed that [AP1-V12]6 fluorescence 
intensity was higher in the target tumor with negligible fluorescence in off-target organs, 
including the lung, spleen, and heart [45]. 
 
A 12-mer peptide, SP90 (SMDPFLFQLLQL), identified using biopanning against BT483 breast 
cancer cells binds specifically to different breast cancer cell lines such as MDA-MB-231, MCF-
7, BT483, SK-BR-3, and MDA-MB-361.  Using mice bearing BT483-derived tumor xenografts, 
it was found that PC90 (phage carrying SP90 peptide) selectively accumulated in tumor tissue 
compared to control tissues.  Moreover, when PC90 was co-injected with the SP90 peptide, it 
competitively inhibited PC90 binding to the tumor tissue [46].  PEGylated liposomal 
doxorubicin decorated with SP90 peptide (SP90-LD) decreased tumor volume by 2.3-fold 
compared to liposomal doxorubicin (LD) in SCID mice bearing BT483-derived xenografts.  No 
detectable reduction in body weight or WBC count was observed in SP90-LD group compared to 
the LD group [46]. 
 
PROSTATE CARCINOMA.  Zitzmann et al. used a 12-mer phage-display peptide library to 
screen for ligands for the DU-145 prostate carcinoma cell line [47]. After six rounds of selection, 
all sequenced phage clones displayed the same peptide called DUP-1 (FRPNRAQDYNTN).  
Synthetic DUP-1 peptide bound and internalized in prostate carcinoma DU-145 and PC-3 cells 
with the highest binding rate after 5 minutes, but not in normal HUVEC or the normal prostate 
cell line PNT-2.  In vivo results showed that DUP-1 peptide accumulated specifically in DU-145 
and PC-3 xenografts, and perfusion decreased the non-specific accumulation in tissues such as 
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blood and kidney.  In vivo biodistribution in the AT-1 rat prostate adenocarcinoma model 
showed that DUP-1 accumulated in prostate tumor tissue three times more compared to normal 
prostate tissue.  DUP-1 degraded in human, mouse and rat serum within∼ 10 min.  In a 
subsequent study, the peptide structure was optimized to increase its stability in vivo [48].  
 
HEPATOCELLULAR CARCINOMA.  In vitro phage-display peptide library screening 
against recombinant human epidermal growth factor receptor (hEGFR) led to the identification 
of peptide GE11 (YHWYGYTPQNVI).[49]  Synthetic free GE11 peptide and EGF inhibited 
phage binding to hEGFR, as well as the EGFR-positive human hepatocarcinoma cell line 
SMMC-7721 with binding affinity (Kd) of 22.3 nM.  These results revealed the binding 
specificity of GE11 peptide for EGFR and the overlap of EGF and GE11 binding sites. 
Intravenous injection of 125I-labeled GE11 in mice specifically accumulated in SMMC-7721 
tumor in mouse xenografts, and the radioactivity in tumor was reduced by 4.5-fold at 4 h post-
injection when excess unlabeled peptide was coinjected with the labeled peptide.  The same 
study further demonstrated that GE11-coated PEI/DNA polyplexes could target mice bearing 
subcutaneous SMMC-7721 tumors in vivo, and caused an 18-fold increase in luciferase 
expression in the tumor compared with non-coated PEI/DNA polyplexes.  When the gPEI/DNA 
was coinjected with free GE11 peptide, the gene expression decreased by 5-fold [49].  
 
In another study, Du et al. screened a phage-displayed peptide library in vitro against the human 
hepatocellular carcinoma cell line BEL-7402 [50].  Phage bearing TACHQHVRMVRP (WP05) 
peptide bound specifically to BEL-7402 cells.  FAM-Labeled WP05 peptide bound to four kinds 
of liver cancer cell lines (BEL-7402, BEL-7404, SMMC-7721, and HepG2), but not the normal 
liver cell line as shown by using fluorescence microscopy and flow cytometry.  WP05 phage 
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injected intravenously into mice bearing BEL-7402 tumors accumulated specifically in the tumor 
as compared to normal mouse liver tissue. 
 
Peptide A54 (AGKGTPSLETTP), identified using in vivo phage-display against hepatoma cell 
line BEL-7402, was conjugated to micelle surfaces and A54–PEG–CS–SA micelles were 
retained primarily by the tumor xenografts in BEL-7402 human hepatoma nude bearing mice.  
Further, the targeting ability of A54 micelles carrying Dox was supported by tumor inhibition by 
86% in the A54–PEG–CS–SA/Dox treated group compared to 74% in the Dox treated group. 
Formulation A54–PEG–CS–SA/DOX displayed reduced toxicity, mostly likely due to high 
targeting efficiency and reduction of heart distribution [51]. 
 
PANCREATIC CANCER.  Pancreatic cancer specimens show higher levels of growth factor 
receptor-bound protein 7 (Grb7) than their corresponding normal pancreatic tissue specimens, 
and this higher expression level is correlated with lymph node metastasis [52].  Pero et al. 
demonstrated that Grb7 siRNA abrogated Grb7 expression and resulted in reduced pancreatic 
cancer cell migration into fibronectin.  A non-phosphorylated peptide inhibitor of Grb7 SH2 
domain, G7-18NATE, which was previously identified using phage display technology, was 
conjugated to a penetratin sequence for targeting and internalization into human pancreatic 
cancer cells (Panc-1) for evaluation of metastasis inhibition [53].  Treatment of cells with the 
peptide conjugate did not alter proliferation, but it did reduce migration into fibronectin.  In vivo, 
BALB/c mice injected intraperitoneally with Panc-1 cells followed by Grb7 peptide inhibitor 
over 2 weeks showed drastically limited pancreatic tumor cell migration and metastases.  
Another phage screening against irradiated Capan-2 human pancreatic adenocarcinoma cells led 
to the identification of peptide PA1 (SHGFSRHSMTLI) [54].  Peptide PA1 was internalized into 
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irradiated Capan-2 cells but not into non-irradiated cells, and intraperitoneally injected PA1 
targeted subcutaneous xenografts of irradiated Capan-2 tumors in mice, but not in non-irradiated 
xenografts. 
 
GASTRIC CANCER.  Akita et al. identified a tri-peptide motif, KLP, through a phage-
displayed peptide library against peritoneal tumors of gastric cancer in BALB/nu mouse 
xenografts [55].  After intraperitoneal injection into mice, phage displaying the KLP peptide 
displayed a 64-fold increase in binding to peritoneal tumors compared to control phage, and were 
primarily accumulated in tumors rather than in normal organs. Synthesized peptide with the KLP 
motif (SWKLPPS) also showed a strong binding to peritoneal tumors and SWKLPPS-decorated 
liposomes accumulated in the peritoneal metastases more efficiently than non-coated liposomes.  
Furthermore, treatment with liposomes conjugated with SWKLPPS loaded with Dox 
accumulated more in tumors and also enhanced the anti-proliferative effects of Dox compared to 
non-targeted control liposomes. 
 
VASCULAR TARGETING PEPTIDES 
Molecular, structural, and functional studies have revealed extensive differences between normal 
vasculature and tumor blood vessels, which can be used in selective tumor targeting.  Tumor 
blood vessels were shown to be leaky and circuitous [56].  In addition, angiogenic tumor blood 
vessels express molecular markers at low levels or can be entirely absent in resting quiescent 
blood vessels, and the ease of accessibility of these surface proteins by the blood stream makes 
them ideal targets [57].  Furthermore, malignant tumor cells are prone to mutations. In contrast, 
the tumor vasculature cells are genetically more stable and less susceptible to drug resistance 
[58].  Collectively, such favorable characteristics highlight the significance of the vascular 
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targeting approach in cancer therapy.  Numerous peptides homing specifically to tumor blood 
vessels have been identified (Table 1).  Many of the specific molecular markers in tumor vessels 
(such as integrins) are associated with angiogenesis.  Angiogenesis is the formation of new 
capillaries from pre-existing vessels for tumor nourishment and progression.  Anti-angiogenic 
therapy acts by eliminating new vasculature and has proven to be a promising concept in tumor 
targeting based on the destruction of tumor microvasculature [59].  Peptide motifs RGD [60] and 
NGR[34], discovered through in vivo phage display, represent the first generation of vascular 
homing peptides, and these peptides will be discussed in detail. 
 
RGD Motif.  The peptide motif RGD (Fig. 2) was originally discovered in vitro in peptides that 
bind to different integrins overexpressed in tumor vasculature.[61, 62] Thereafter, the RGD 
peptide was shown to home in vivo to malignant melanoma and breast carcinoma xenografts in 
tumor-bearing mice [60].  The RGD peptides have high affinity for the integrins expressed in the 
angiogenic vasculature, in particular, αvβ3 and αvβ5 [62].  Along with integrin binding, RGD 
peptides are also capable of internalizing into the cells, interrupting the angiogenesis process that 
leads to cell death.  Considerable numbers of synthetic RGD variants has been developed, 
including ACDCRGDCFCG (RGD-4C) and CRGDC (RGD-2C) which have different beneficial 
abilities in drug delivery [63]. Potent anti-angiogenic properties of RGD-4C have been shown 
using knockout mice experiments [64].  The use of tumor targeting peptides in general and RGD 
peptide in particular was validated with a cyclic pentapeptide RGD analogue, Arg-Gly-Asp-[65]-
Val or cyclo(RGDfV) known as Cilengitide® (Fig. 2, EMD 121974, Merck).  Cilengitide 
possesses anti-angiogenic activity and is used in the treatment of glioblastoma. It is a selective 
αvβ3 and αvβ5 integrin antagonist.  Despite promising phase I and II clinical trials, its use as an 
anticancer therapeutic has been discontinued due to failure in phase-III clinical trials [66]. 
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Xiong et al. were the first  to report the X-ray structure (PDB code 1L5G) of the extracellular 
segment of αvβ3 in complex with a cyclic pentapeptide RGD analogue, Arg-Gly-Asp-{N-
methyl-Val-} (Fig. 3) [67].  The RGD sequence makes main contact with the integrin where the 
Arg and the Asp side chains point in opposite directions.  The conformation of the RGD motif in 
the pentapeptide matches that of the RGD tripeptide in the natural ligand Echistatin.  The 
arginine guanidinium group interacts with two Asp residues from integrin forming bidentate salt 
bridges, whereas the Asp (carboxylate oxygens) from RGD interacts with a Mn2+ ion and Tyr 
and Asn of integrin forming hydrogen bonds [67].   
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Fig. (2). Chemical structures of RGD peptides, (A) linear RGD, (B) cyclized RGD (Cilengitide 
or cyclo(-RGDfV-) peptide), and (C) RGD dimer. 
 
 
c(RGDfV)Linear RGD
E[c(RGDfK)]2
(A) (B)
(C)
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Fig. (3). Structure of cyclo(RGDf-N[Me]V) in complex with v3 (PDB ID: 1L5G) [67].  
cyclo(RGDf-N[Me]V is shown as a stick model whereas portion of v3 is shown as ribbon 
drawing.  The figure was created using SWISS PDB viewer. 
 
 
Peptide Affinity Optimization.  Structure-activity relationship (SAR) studies have been employed 
to the lead RGD sequence identified from phage display to identify structural features for 
enhancement of binding affinity and specificity of these molecules to ανβ3 integrins.  The 
flanking residues can affect the conformation of the RGD motif as well as control the peptide 
folding.  In addition cyclization can confer rigidity to the peptide structure, greatly improving 
selectivity of the promiscuous RGD sequence for a specific integrin subtype.  As shown in Fig. 
2, specificity and affinity for αvβ3 integrin is enhanced in RGD peptide ligands by ring closure 
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and flanking amino acids, which force the arginine and aspartic acid side residues into the proper 
conformation.  SAR studies demonstrated that RGD peptide receptor binding affinity and 
selectivity can be enhanced by cyclization via linkers, such as thioether, disulfide, and rigid 
aromatic rings or other heterocycles [68, 69].  For instance, ACDCRGDCFCG (RGD-4C) with 
two disulfide bonds was at least 20-fold more potent than similar RGD peptides with a single 
disulfide bond, and 200-fold more potent than commonly used linear RGD peptides [62].  A 
cyclic RGD pentapeptide framework is found to increase the binding affinity and selectivity 
regardless of which amino acid is placed at position 5, viz., c(RGDfK), c(RGDfE), and 
c(RGDfV).  All three analogues show similar binding affinity to integrin [69].  As mentioned 
above, Cilengitide® targeting integrins ανβ3 and ανβ5 reached up to phase III trials for brain 
cancer glioblastoma.  However it failed phase III clinical trials. When used in combination with 
standard temozolomide (TMZ) and radiotherapy (RT) in treatment of patients with newly 
diagnosed glioblastoma and with methylated O6-methylguanine-DNA methyltransferase 
(MGMT) gene promoter, the peptide failed to show any significant effect on patient survival 
compared to the control group [66]. 
 
To further improve peptide binding affinity, concepts like dimerization and multivalency have 
been utilized [70]. Recently, several laboratories have used bivalent or multivalent cyclic RGD 
moieties to attain high affinity (∼10 nM) for αvβ3.  Since the natural mode of interactions 
between integrin αvβ3 and RGD-containing proteins such as vitronectin and fibronectin may 
involve multivalent binding sites, multivalent cyclic RGD peptides could provide more effective 
peptide ligands with enhanced targeting efficacy and cellular uptake [71].  For instance, cyclic 
RGD dimers such as E[c(RGDfK)]2 and E[c(RGDyK)]2 have been developed as targeting 
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biomolecules for imaging purposes (Fig. 2C) [72].  The dimers yield enhanced binding rate as 
binding of one RGD motif significantly increases the local concentration of the second RGD 
motif.[72]  Similarly, RGD peptide tetramers showed better integrin binding affinity than 
monomeric and dimeric analogues.  Different linkers are used to conjugate monomeric peptides 
to one another, such as small flexible molecules (ethylene glycol units) or larger carriers (leucine 
zipper variant or the IgG Fc-region) [73].  Multivalency not only significantly improves the 
affinity but also facilitates internalization and may increase half-life combining the advantages of 
antibodies and small molecules [74, 75]. 
 
Improving Tumor Penetration.  The success of targeted cancer therapy depends on the ability of 
the targeted drug molecules to reach primary and/or metastatic sites, and to penetrate deeply into 
the tumor.[76]  Peptide sequence CRGDKGPDC, named internalizing RGD (iRGD), has been 
identified by screening cyclic CX7C peptide library against tumor vasculature of human prostate 
cancer.[75]  Unlike the conventional RGD peptides discussed above, the iRGD motif has the 
ability to penetrate and become dispersed throughout the tumor tissue.[75, 77]  This motif can 
also bind to other types of cancer including xenografts of pancreatic ductal and breast cancer.  
The mechanism underlying the iRGD tissue penetration occurs through a three-step process. 
First, the RGD motif binds to αvβ integrins on the cell surface.  A proteolytic cleavage then 
exposes a binding motif for neuropilin-1 (CRGDK fragment), and this mediates the penetration 
into tissue and cells.  The binding motif follows a specific consensus R/KXXR/K (named C-end 
rule),[76] that is known to bind neuropilin-1, a known mediator of vascular permeability induced 
by vascular endothelial growth factor (VEGF).[78]  Accordingly, the CendR peptides increase 
vascular leakage and tissue penetration.  The iRGD peptide enhanced the delivery of 
chemotherapeutics to solid tumors.  In fact, the authors showed that conjugation of the peptide 
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was not required.  Co-administration of iRGD with the anticancer drug doxorubicin, 
nanoparticles carrying doxorubicin, or trastuzumab (a monoclonal antibody) improved the 
therapeutic index of the drug [79]. 
 
NGR Motif.  The tripeptide motif NGR (Fig. 4), discovered by in vivo screening of phage 
libraries on human breast carcinoma xenografts, homes specifically to tumor blood vessels and 
other types of angiogenic blood vessels where it binds to aminopeptidase N (APN) receptor or 
CD13 receptor [34].  Several NGR-containing peptide sequences have been identified, such as 
disulfide bond cyclized CNGRC (cCNGRC) and cCVLNGRMEC, as well as linear analogues 
GNGRG and NGRAHA [16].  The peptide sequence cCNGRC has been coupled to different 
anticancer compounds such as doxorubicin [80], cisplatin [81], proapototic peptides [82], and 
tumor necrosis factor- (TNF).[83]  NGR conjugated to TNF (NGR-hTNF) is in phase II clinical 
trials [84, 85].  An N- to C-terminal amide bond cyclized cKNGRE sequence is also reported for 
tumor targeting applications.[86]  Pentapeptide analogues of NGR synthesized via on-resin click 
chemistry show specific binding to purified CD13 receptor as well as to cell lysates from CD13+ 
SKOV-3 cancer cells.[87] 
 
Structure-function studies with NGR sequences showed that the disulfide constraint enhances 
interaction with CD13 receptor, improving targeting ability ten-fold for cyclic CNGRC 
compared to linear GNGRG peptides.[88]  Further, modification of cCNGRC with proline to 
produce cCPNGRC improved overall binding affinity to APN, and led to 30-fold lower IC50 for 
the inhibition of APN proteolytic activity.[89] Peptides containing the NGR motif can undergo 
spontaneous deamidation and generate Asp and isoAsp degradation products (Fig. 5).[90, 91]  
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Flanking residues play an important role in NGR to isoaspartate-glycine-arginine (isoDGR) 
conversion with concomitant exchange of receptor affinity from CD13 to ανβ3 integrin.[91] 
 
Notably, the NGR sequence is also present in fibronectin (FN), an extracellular matrix protein 
involved in several key cellular processes.[90]  Human FN is a large glycoprotein that contains 
three types of repeating modules, type I, II, and III.  NGR with different flanking residues is 
present in each of the repeating modules of human FN.  Soudy et al. used a peptide array-cell 
binding assay to identify NGR sequences displaying up to a 5-fold increase in binding to CD13+ 
cells and very low binding to CD13- cell lines compared to the lead cyclic CVLNGRMEC 
peptide.  A library of forty-five NGR containing peptides was synthesized in an array on 
cellulose membrane followed by on membrane (direct) screening against CD13+ and CD13- cell 
lines.  New peptide sequences such as YNGRT and CVLNGRSEC displayed high binding 
affinity for the CD13+ cells along with improved in vitro cellular uptake and specificity.  Newly 
identified sequences bear a resemblance to NGR sequences present in human fibronectin [92]. 
 
 
Fig. (4).  Chemical structures of linear NGR (A) and cyclic CNGRC (B). 
(B)
Cyclic CNGRCLinear NGR
(A)
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Fig. (5).  NGR undergoes deamidation by nucleophilic attack of the backbone NH on the Asn 
side chain amide.  Subsequently hydrolysis of the succinimide intermediate leads to the 
formation of isoDGR or DGR. 
 
 
- NH3
Succinimide Intermediate
isoDGR DGR
NGR
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PEPTIDES HOMING TO TUMOR LYMPHATICS 
Peptides targeting tumor lymphatic vessels have also been identified using phage display (Table 
1) [93, 94].  The first peptide identified for lymphatic homing was LyP-1 (CGNKRTRGC) [95].  
This peptide was identified using a combination of ex vivo/in vivo screens on MDA-MB-435 
xenografts in nude mice.  LyP-1 homed to the tumor-associated lymphatic vessels as well as to 
tumor cells in the hypoxic areas of tumors, but did not home to the tumor blood vessels.  The 
LyP-1 receptor is a cell surface form of a mitochondrial protein p32 [96].  The protein p32 shows 
unusual cell surface expression in tumor lymphatics, tumor cells, and a subset of myeloid cells 
which adds to the specificity of LyP-1 homing to tumors [96].  Recently, a peptide named RMS-
II (CMGNKRSAKRPC) was identified to bind to rhabdomyosarcoma cell lines, and showed 
some sequence similarity to LyP-1 [97].  However, RMS-II homed better to RMS xenografts in 
vivo than LyP-1.  Furthermore, RMS-II recognized tumor blood vessels, and not tumor 
lymphatic vessels indicating different specificities of the two peptides [97] . 
 
Another study showed that lymphatics homing peptides LyP-1 and LyP-2 (CNRRTKAGC) with 
homologous sequences, home to lymphatics of different tumor types [98].  LyP-1 recognizes the 
lymphatics and tumor cells in MDA-MD-435 breast carcinoma, MMTV-PyMT breast 
carcinoma, and KRIB osteosarcoma xenografts as well as their metastatic lesions but not in the 
C8161 melanomas, while the LyP-2 peptide homes to the lymphatics of the C8161 melanomas 
and K14-HPV16 skin and cervical carcinomas but not to the MDA-MB-435 tumors [98].  The 
specificity of these peptides was further demonstrated by conjugation of the two peptides with 
different fluorophores followed by simultaneous injection into the same animals.  LyP-1 homed 
only to the lymphatics of MDA-MB-435 tumors and LyP-2 to the lymphatics of K14-HPV16 
cervical carcinomas [98].  These studies indicate that tumor lymphatics are similar to tumor 
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blood vessels, expressing tumor type-specific markers that are distinct from the blood vessel 
markers of the same tumor. 
 
4. CANCER TARGETING PEPTIDES IN DRUG DELIVERY 
Cancer targeting peptides have been extensively studied for tumor-specific drug delivery. Here 
we reviewed key recent examples based on the different strategies for targeting three receptors 
(integrin, aminopeptidase N, epidermal growth factor), and discussed the prospects of such 
constructs to specifically target tumor cells.  Peptide targeted drug delivery is achieved mainly 
by either conjugating cancer specific peptides to chemotherapeutic drugs or using these peptides 
to modify the surface of different drug carriers (nanoparticle, micelles, dendrimers, and 
liposomes) that encapsulate anticancer drugs and deliver them preferentially to targeted tumor 
sites [99, 100].  Peptide-drug conjugates have high specificity and can penetrate the tumor better 
than a large nanocarrier, whereas drug carriers such as liposomes and polymers can carry more 
drug molecules per targeting event and have longer circulation times in blood.  In general, 
tumor-specific delivery of chemotherapeutics by either method increases the therapeutic efficacy 
of anticancer drugs and limits toxicity to normal tissues.  Higher concentrations of drug 
specifically reaching the tumor will decrease the phenomena of incomplete tumor response or the 
emergence of tumor drug resistance. Overall, this will maintain the quality of the cancer patient’s 
life while efficiently attacking the cancer. 
 
PEPTIDE-DRUG CONJUGATES 
Peptide-drug conjugates (PDCs) are being developed for the targeted delivery of drugs to the 
cancer site.  A wide variety of drugs such as antisense oligonucleotides, toxins, chemotherapeutic 
agents and proapoptotic peptides have been conjugated to cancer targeting peptides for site-
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specific delivery [101].  Remarkable success in targeting the antitumor agent cytokine TNF into 
tumors has been reported with RGD and NGR peptides.  The targeted cytokine was effective in 
1,000-fold lower dose than the usual dose, and effectively decreased the side effects associated 
with the high toxicity of the cytokine [102].  A randomized double-blind phase III study of 
NGR-TNF (in combination with chemotherapy or supportive care) started in 2010 in patients 
with malignant pleural mesothelioma [103].  Doxorubicin (Dox) has been conjugated to 
Luteinizing-hormone-releasing hormone LHRH agonist and antagonist peptides for selectively 
targeting cancer cells.  The ability of LHRH-Dox conjugate to inhibit cancer cell growth (i.e., 
breast, prostate, mammary, and ovarian cancer cells) was comparable to that of the 
corresponding individual drugs[102].  In vivo studies indicated that the drug-agonist conjugates 
are less toxic and more potent than the corresponding drug (Dox).  In another study, a Dox-
RGD4C conjugate was synthesized for drug targeting to the vasculature of breast tumor model 
which expresses αvβ3 in the angiogenic blood vessels and the tumor cells. The conjugate proved 
to be equally effective to free Dox in vitro and, more importantly, demonstrated improved 
inhibition of tumor growth and spreading of metastases in mice [34].  In addition to an improved 
efficacy, Dox-RGD4C conjugate also displayed reduced toxicity to liver and heart.  Soudy et al. 
showed that conjugating Dox to peptide 18-4 breast cancer-specific peptide through ester linkage 
was 6-10 times more selective for breast cancerous cells (MCF-7 and MDA-MB-435) over 
noncancerous cells (HUVECs and MCF-10A).  In addition, ester conjugate displayed similar 
toxicity to free Dox toward the breast cancerous cells and 40 times less toxicity toward the 
noncancerous cells.  The conjugate was 4-fold more toxic toward the Dox resistant MDA-MB-
435-MDR cells than the free Dox [104]. 
 
29 
 
Similarly, antibody-drug conjugates (ADCs) can be very effective. An ADC, Ado-trastuzumab 
emtansine (antibody-drug conjugate pairing a HER2 blocker with a tubulin inhibitor, Genentech) 
for HER2-positive metastatic breast cancer was approved recently and is in clinical use for 
cancer treatment [105].  PDCs offer solutions for several problems encountered with ADCs, as 
PDCs allow control over peptide-drug ratio and the chemistry of conjugation is much easier. 
Owing to the small size of peptide, it can better escape from the vasculature and diffuse through 
the interstitial space of tumors. There is also a low chance of eliciting an immune response when 
compared to antibodies.  Another advantage is that some PDCs were found to escape p-
glycoprotein efflux that causes drug resistance. On the contrary, the activity of many ADCs was 
poor in cells that express these efflux pumps [106, 107].  One study attributed the poor efficacy 
of ADCs to their degree of hydrophobicity, as most of the reported p-glycoprotein efflux pump 
substrates are hydrophobic. They hypothesized that an antibody conjugated to drugs via a 
hydrophilic linker would be a poor substrate of the efflux pump, thus circumventing drug 
resistance in ADCs [108]. PDCs have also reached clinical trials.  A peptide-drug conjugate, 
GRN1005 (phase II trials), composed of three molecules of paclitaxel covalently linked to 19-
mer angiopep-2 peptide (TFFYGGSRGKRNNFKTEEY) targets the low-density lipoprotein 
receptor-related protein 1(LRP-1).  LRP-1 is a highly expressed receptor on the surface of the 
blood brain barrier.  GRN1005, a prodrug, showed therapeutic efficacy in patients with advanced 
solid brain tumors, brain metastases and patients who failed prior taxane treatment.  Such 
advances emphasize the positive prospects of PDCs in cancer treatment [103].  
 
PEPTIDE MODIFIED NANOCARRIER 
Cancer targeting peptides surface conjugated to nanocarriers offers several advantages compared 
to the direct conjugation methods highlighted above.  Nanocarriers hold multiple ligands on each 
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particle allowing multivalent interactions between the ligands and the receptors, which results in 
more proficient targeting.  Beside, carriers simply preserve the drug from degradation in 
physiological conditions and prevent its direct contact with normal tissues thereby minimizing 
undesirable off-target effect.  Nanocarriers are larger in size (10-500 nm) compared to traditional 
drugs that are easily filtered off by the renal excretion route (cut off size for renal excretion is 5 
nm). This extends the drug half-life and enables its extended release, improving efficacy.  
Different sorts of nanocarriers functionalized with peptide tumor targeting ligands have been 
investigated and some representative recent studies are listed in Table 2. 
 
The use of peptide-modified drug loaded nanocarriers such as liposomes, micelles, and polymers 
for tumor-targeted delivery has been extensively studied [109, 110].  Reported studies showed 
that peptide-targeted nanocarriers containing anti-cancer agents are more effective in reducing 
tumor growth and in enhancing survival in mice when compared to non-targeted ones.  Peptide 
RGD is the first tumor-targeting peptide that has been used to modify nanocarriers to improve 
the therapeutic efficacy of the loaded chemotherapeutic drug.  RGD4C-decorated polymeric 
micelles effectively improved the therapeutic efficacy of Dox conjugated to the core forming 
block either through acid cleavable hydrozone or stable amide linkages in SCID mice bearing 
wild or resistant MDA-MB-435 tumor, respectively [111].  In another study, NGR liposomal 
doxorubicin was administered to mice in three cycles of 3 mg/kg/week dosing.  The targeted 
liposomal formulation showed rapid tumor regression and metastasis inhibition while mice 
treated with mismatched peptide targeted liposomal Dox formed large neovasculature [112].  We 
found that peptide p160 conjugation of the polymeric micelles enhanced the selective 
cytotoxicity of encapsulated paclitaxel (PTX) against MDA-MB-435 cancer cells over normal 
HUVEC and MCF-10A cells [113].  Further, a liposomal formulation of Dox surface-coated 
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with a p160 analogue (peptide 18-4) showed better cytotoxicity against MDA-MB-435 compared 
to non-targeted liposomes [114].  NOD-SCID mice bearing MDA-MB-435 xenografts treated 
with peptide 18-4 conjugated liposomal Dox displayed a 5-fold reduction in the mean relative 
tumor volume compared to mice treated with non-targeted Dox liposomes [115].  These 
examples highlight the potential of peptide-nanocarrier conjugates as drug carriers, which are 
being increasingly pursued by drug delivery researchers for targeted therapy of cancer. 
 
5. CANCER TARGETING PEPTIDES IN DIAGNOSTICS 
There is great interest in the use of cancer targeting peptides for in vivo diagnostic applications 
due to their high tumor selectivity [116].  Peptides are considered as ideal receptor‐guided 
vectors in tumor imaging.  This is derived from their favorable pharmacokinetic characteristics.  
Peptides can tolerate harsh conditions such as pH, temperature, etc. during chemical 
modifications and diverse radiolabeling techniques.  Because of their compact size, peptides 
have tumor uptake with concomitant rapid clearance from blood and non‐target tissues.  Peptides 
have been attached to a variety of dyes and fluorescently labelled nanoparticles, such as quantum 
dots, for in vivo optical fluorescence imaging [117].  Different peptide sequences have shown 
promising results in tumor imaging.  The best example is somatostatin analogs that target 
somatostatin receptor overexpressed in neuroendocrine tumors.  111In-DTPA-octreotide (111In-
Octreosan) is the first US Food and Drug administration approved diagnostic radiopeptide for the 
imaging of patients with neuroendocrine tumors [118].  Other naturally occurring peptides 
sequences (such as bombesin/gastrin releasing peptides) have shown great promise in the 
visualization of BN/GPR overexpressing tumors including prostate, breast, and lung cancer 
[119].  A number of other specific peptides, such as vasoactive intestinal peptide, neurotensin, 
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and cholecystokinin/gastrin are currently under preclinical or clinical investigation to determine 
their true potential in the diagnosis or treatment of human cancer [120]. 
 
The RGD peptide has been used for targeted delivery of various imaging agents.  RGD-
conjugated radiolabeled iron oxide nanoparticles were used to image subcutaneous human 
glioma xenograft tumors using a positron emission tomography/magnetic resonance imaging 
(PET/MRI) dual imaging system [121].  Moreover, the RGD-targeted MRI-detectable 
fluorescent liposomes and the RAD-conjugated liposomes (as a control for specificity) 
accumulated in the tumor by different mechanisms.  The RGD-liposomes specifically associated 
with blood vessels that expressed v3 at the angiogenic endothelium, whereas the RAD-
liposomes were located in the extravascular compartment, indicating extravasation of the 
liposomes [122].  Radioactive RGD peptides are considered a potential class of radiotracers for 
tumor diagnosis and monitoring therapeutic outcomes in cancer patients [123].  Tracers like 
[18F]-galacto-c(RGDfK) as well as [18F]-bearing tracers with RGD4C and PEG linker, are being 
investigated for noninvasive imaging of integrin expression in cancer patients.  In addition, 
cyclic NGR peptide (cNGR) was successfully used for targeted imaging of angiogenic vessels in 
the ischemic heart [124].  Additional recent studies representing the use of peptide-tumor ligands 
in cancer imaging and diagnosis are listed in Table 3. Overall, these studies show the potential 
use of peptide-targeted delivery of imaging agents for tumor imaging and visualization. 
 
6. CONCLUSIONS AND OUTLOOK 
Various in vitro and in vivo preclinical studies have shown that tumor-targeting peptides are 
powerful candidates for ligand targeted delivery of drugs, drug nanocarriers and diagnostics 
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specifically to tumors. Although a growing number of tumor-targeting peptides are being 
identified by different screening tools, the number successfully reaching clinics is not meeting 
expectations.  Peptides as drug delivery vehicles suffer from numerous obstacles and have 
several important parameters that need to be optimized for the successful translation of these 
targeting constructs to clinical applications.  For instance, peptides have a short half-life in 
biological fluids, caused mainly by proteolytic cleavage and renal clearance. Increasing the 
peptide stability against proteolytic digestion can be achieved by incorporating non-
proteinogenic amino acids into the peptide sequence, or via peptide cyclization.  On the other 
hand, increasing the molecular weight of the peptide above the renal clearance limit by coupling 
to a carrier molecule such as albumin would decrease its renal clearance.  Peptides, due to their 
small size, suffer from low binding affinity to their putative receptor on tumor cells. Building 
multimeric targeting structures by grafting several peptides onto a multi-headed core may 
compensate for the low binding affinity to achieve effective targeting. 
 
Peptide ligand binding to the tumor expressed receptor is a crucial step in initiating signals, and 
the study of ligand-receptor interaction can reveal the molecular basis for both binding and 
receptor activation.  Synthetic peptide libraries are useful tools for carrying out such structure–
activity studies. Peptide leads identified using phage display can be further optimized by the use 
of synthetic peptide libraries which leads to smaller derivatives with increased tumor penetration 
and target affinity.  In addition, structure-function studies are important for identifying the role of 
each amino acid in receptor recognition and targeting.  For the successful application of peptides 
in the development of nanosystem constructs, special consideration should be made during the 
synthesis.  For instance, optimal peptide density for cell-targeting capability and internalization 
should be obtained, and the distance of the peptide from the nanostructure surface should be 
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adjusted using a linker in order to maintain the conformation of the peptide required for high 
affinity binding to the target.  Peptide density of nanoparticle surface can affect the subsequent 
ligand/receptor binding interactions, as well as particle stability, drug loading and release 
characteristics.  Optimization of these characteristics could further improve the therapeutic 
potential of cancer targeting peptides in drug delivery systems.  It is certain that with several-fold 
improvement in the therapeutic efficacy of cancer drugs and development of efficient cancer 
imaging probes using cancer targeting peptides, we are bound to see more peptide-based systems 
entering into clinical trials during the coming years. 
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Table 2.  A few representative nanocarriers functionalized with tumor targeting peptide ligands 
 
Carrier System Targeting 
Peptide 
Drug In vivo System In Vivo Results [reference] 
Integrins 
Methoxy PEG-PLGA-PLL Nanoparticles cRGD Mitoxantrone 
(DHAQ)  
MDA-MB-231 
breast cancer-
bearing mice 
Specific uptake in tumor ( 2.4-fold 
increase), 4-fold decrease in tumor 
volume and higher tumor growth 
inhibition compared to free drug, and 
low inherent in vivo physiological 
toxicity.[125] 
Methoxy PEG-PLGA-PLL Nanoparticles cRGD Bufalin SW620 colon 
cancer-bearing mice 
Better tumor targeting and longer residue 
time in vivo, 2-fold decrease in tumor 
volume, and higher tumor growth 
inhibition compared to free drug.[126] 
Methoxy PEG-b-P(Glu) polymeric 
micelles and 
Maleimide-PEG-b-P(Glu) polymeric 
micelles  
cRGD (1,2-Diamino 
cyclohexane)
platinum(II) 
or (DACHPt) 
U87MG 
glioblastoma tumor-
bearing mice 
Higher tumor accumulation, higher 
permeability from vessels into the tumor 
parenchyma compared to the control 
PM, 10-fold decrease in tumor volume, 
compared to saline treated group.[127] 
HSPC/CHOL/MBPE/DSPE-PEG2000 
(54.5:38.0:2.5:5.0 molar ratio) 
cRGD Doxorubicin Male Sprague-
Dawley rats 
Higher cell uptake by U87MG cells 
compared with non-targeted, improved 
pharmacokinetics in rats, longer 
systemic circulation time (8.3-fold 
increase in area under the curve) 
compared with free Dox. [128] 
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Aminopeptidase N 
Sterically stabilized liposome (SSL) NGR Paclitaxel HT1080 tumor-
bearing mice 
Better in vivo pharmacokinetic profile, 
(10-fold increase in half-life, 2.5 fold 
increase in bioavailability compared to 
Taxol treated group).   The average 
tumor weight was 11 times less than 
saline treated group. In addition, no 
significant weight loss was 
observed.[129] 
DSPE-PEG micelles 
 
NGR Paclitaxel C6 glioma tumor–
bearing mice  
Tumor weight inhibition (% decreased 
by 7-fold compared to Taxol treated 
group). Higher anti-angiogenic activity 
compared to saline treated group.[130]  
PEG = poly(ethyleneglycol);  PLGA = poly(lactic-co-glycolic acid);  PLL = poly-L-lysine;  b-P(Glu) =  b-poly(L-glutamic acid);  HSPC= 
hydrogenated soybean phosphatidylcholine;  CHOL = cholesterol; MBPE = maleimidobenzoyl phosphatidylethanolamine; DSPE=1,2-
distearoyl-sn-glycero-3-phospho ethanolamine 
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Table 3.  A few representative tumor targeting peptide ligands in cancer imaging 
Imaging Probe 
(Application) 
Targeting 
Peptide 
In vivo System In Vivo Results [reference] 
Integrins 
68 Ga-TRAP(RGD)3 
(PET imaging) 
c(RGDfK) 
peptide 
trimer 
CD-1 athymic nude 
mice bearing 
M21/M21L human 
melanoma 
xenografts  
68Ga-TRAP(RGD)3 exhibits 7.3 and 7.6 fold higher affinity to αvβ3 
integrins compared to 18F-Galacto-RGD and 68Ga-NODAGA-
RGD in M21 cells.  Excellent pharmacokinetics in mice, fast renal 
clearance, and high in vivo stability. Higher tumor specific uptake 
(6 fold) than that of the other tracers. [131] 
G5.NHAc-RGD-Fe3O4 
NPs  
(Magnetic resonance 
imaging) 
G5.NH2-
RGD 
poly(amido
amine) 
dendrimers  
C6 glioma  tumor-
bearing nude mice 
Targeted NPs show good water and colloidal stability, a relaxivity 
(r2) of 5.899 mM-1s-1, and good hemocompatibility and 
biocompatibility over the studied concentration range. Cellular 
uptake studies, in vitro and in vivo MR imaging showed that the 
developed G5.NHAc-RGD-Fe3O4 NPs have a high affinity for C6 
glioma cells in mice that overexpress αvβ3 receptors compared to 
non-targeted nanoparticles.[132] 
68Ga-NOPO−cRGD 
(PET imaging) 
cyclo(RGD
fK) 
M21/M21L 
xenografted athymic 
CD-1 nude mice 
Rapid and specific uptake in M21 tumor xenografts, and was 
found stable in vivo. Very rapid pharmacokinetics and renal 
clearance were observed, enabling high-contrast PET imaging 
shortly after tracer administration, which renders it an interesting 
tracer for PET imaging of integrin status in an outpatient clinical 
setting.[133] 
64Cu-integrated Au NMs  
RGD ([64Cu]Au NMs) 
cRGD U87MG 
glioblastoma 
Two fold increase in tumor uptake compared to non-targeted 
nanrods. The cell uptake of RGD-Au NRs was nearly 2.8 and 3.0 
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(PET imaging) xenograft model times that of Au NRs and RGD-Au NPs þ blocking (RGD-Au NRs 
plus free RGD to block the target), respectively.[134] 
[18F]6Glc-RGD), [18F]Gal-
RGD, [18F]Mlt-RGD, 
[18F]Cel-RGD) 
(PET imaging) 
c(RGDfPra
) 
U87MG tumor-
bearing nude mice 
[18F]6Glc-RGD and [18F]Mlt-RGD showed significantly decreased 
liver and kidney uptake by PET relative to the 2-
[18F]fluoroglucosyl analog [18F]2Glc-RGD, and showed specific 
tumor uptake in vivo.  [18F]Mlt-RGD revealed higher uptake and 
retention in the U87MG tumor comparable to that of [18F]Galacto-
RGD. The uptake for [18F]Galacto-RGD in the M21 tumor model 
is twice as high as that of [18F]Mlt-RGD in U87MG tumors.  
Difference could be most likely ascribed to differences in the 
overall αvβ3 or αvβ5 integrin expression between the M21 and 
U87MG tumors. While [18F]6Glc-RGD has favorable tumor-to-
blood ratios in the U87MG tumor model, but only low tumor 
retention, [18F]MltRGD proved to have slower blood clearance but 
even less uptake in the kidney and liver.[135] 
Aminopeptidase N 
64Cu-DOTA−NGR1 and 
64Cu-DOTA−NGR2  
(microPET imaging) 
GGGCNG
RC 
Female athymic 
nude mice CD13-
positive HT-1080 
fibrosarcoma 
xenografts   
64Cu-DOTA−NGR1 and 64Cu-DOTA−NGR2 showed significant 
reduction of tumor uptake with a co-injected blocking dose of 
cyclic NGR. 64Cu-DOTA−NGR2 displayed higher tumor uptake 
and slower tumor washout in CD13-positive HT-1080 tumor 
xenografts as compared to 64Cu-DOTA−NGR1.[136]  
68Ga-NOTA-c(NGR) 
(PET imaging) 
c[KNGRE]
-NH2 
Orthotopic and 
heterotopic 
transplanted 
mesoblastic 
nephroma (NeDe) 
bearing Fischer-344 
rats 
68Ga-NOTA-c(NGR) uptake was significantly lower in abdominal 
organs in comparison with 68Ga-NODAGA-[c(RGD)]2. In NeDe 
tumor bearing rats  68Ga-NOTA-c(NGR) showed higher 
accumulation in the tumors than that of the 68Ga-NODAGA-
[c(RGD)]2. Using orthotopic transplantation, metastases were 
developed which showed specific 68Ga-NOTA-c(NGR) 
uptake.[137] 
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 TRAP= (1,4,7-triazacyclononane-1,4,7-tris[(2-carboxyethyl)methylenephosphinic acid]), Glc= glucosyl , Gal=galactosyl , Mlt= 
maltosyl, Cel= cellobiosyl. NOPO= (1,4,7-triazacyclononane-1,4- bis[methylene(hydroxymethyl)phosphinic acid]-7-[methylene- 
(2-carboxyethyl)phosphinic acid]. Fe3O4 NPs= Iron oxide NPs. PET= positron emission tomography. DOTA= 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid. NOTA= 1,4,7-triazacyclononane-triacetic acid 
 
ABBREVIATIONS 
 
ADCs = antibody-drug conjugates   
APN =aminopeptidase N  
Dox = Doxorubicin 
EGFR= Epidermal growth factor receptor  
ELP = elastin like polypeptide   
FGF = fibroblast growth factor  
FN = fibronectin  
hEGFR= human epidermal growth factor receptor  
IL-4R= interleukin 4 receptor  
iRGD = internalizing RGD  
LD= liposomal doxorubicin  
LHRH =luteinizing-hormone-releasing hormone  
LRP-1= low-density lipoprotein receptor-related protein 1 
MGMT= methylated O6-methylguanine-DNA methyltransferase 
OBOC = one-bead one compound 
PDCs= peptide-drug conjugates 
PEG = poly(ethyleneglycol) 
PTX= paclitaxel  
RGD = Arg-Gly-Asp 
RT = radiotherapy  
SAR = structure-activity relationship  
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TMZ = temozolomide 
TNF- α = tumor necrosis factor  
TGF-α = transforming growth factor  
TK = tyrosine kinase  
VEGF =vascular endothelial growth factor  
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